Recent Updates
Recently added Catalysts
SKYE Negative Sentiment Score: 25/100

SKYE LAWSUIT ALERT: The Gross Law Firm Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Key Takeaway: The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit related to the company's lead product, nimacimab. The lawsuit claims that the defendants provided materially false statements and misrepresented the drug's effectiveness and prospects. The class period for affected shareholders spans from November 4, 2024, to October 3, 2025, with a deadline for lead plaintiff applications set for January 16, 2026. Shareholders are encouraged to register to participate in the case without any cost or obligation.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit alleges Skye Bioscience made misleading statements about nimacimab's effectiveness.
  • Claims of overstated clinical, regulatory, and commercial prospects of their lead product candidate.
  • Investors may incur losses due to potential inflation of stock from false information.

Full Press Release Details

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE).
Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 4, 2024 to October 3, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i)The Company’s lead product candidate, nimacimab, was less effective than defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: January 16, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/?id=180995&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SKYE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is January 16, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Skye Bioscience, Inc. shareholders?

The class period for Skye Bioscience, Inc. is from November 4, 2024, to October 3, 2025.

What allegations are made against Skye Bioscience?

The allegations indicate that Skye Bioscience misled investors about the effectiveness of nimacimab.

Is there a deadline for shareholders to register for the class action?

Yes, the deadline to register and seek lead plaintiff status is January 16, 2026.

What happens after registering as a shareholder?

Registered shareholders will receive updates through portfolio monitoring software regarding the case.

Is there any cost to participate in the case?

There is no cost or obligation to participate in this class action case.

Last updated: Dec 22, 2025